

References

- Alexander SW, Wade KC, Hibberd PL, et al. (2002):** Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. *J Pediatr Hematol Oncol* ;24:38-42.
- Ammann RA, Bodmer N, Hirt A, et al. (2010):** Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study. *J Clin Oncol* ;28:2008-2014.
- Andreas H, Groll MD, Thomas J, et al. (2002):** Invasive fungal infections in neutropenic cancer patients: Current approaches and future strategies. *Infections in medicine* ;19(7):326-334.
- Aquino VM, Herrera L, Sandler ES, et al. (2000):** Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. *Cancer* ;88:1710-4.
- Avoka M. (2006):** Emerging problem pathogens: A review of resistance patterns over time. *Int J Infect Dis* ;10(Suppl 2):S3-8.
- Baddley JW, Stroud TP, Salzman D, et al. (2001):** Invasive mold infections in allogeneic bone marrow transplant recipients. *Clin Infect Dis* ;32:1319-1324.
- Badea M and Badea D. (2002):** Ceftriaxone in febrile granulocytopenic patients with hematological malignancies. *The Hematology journal* ;3(1):213.
- Badiee P, Kordbacheh P, Alborzi A, Malekhoseini SA, Ramzi M, Mirhendi H, et al. (2009):** Study on invasive fungal infections in immunocompromised patients to present a suitable early diagnostic procedure. *Int J Infect Dis* ;13(Issue 1):97-102.
-

- Baglin TP, Gray JJ, Marcus RE & Wreghitt TG. (1989):** Antibiotic resistant fever associated with herpes simplex virus infection in neutropenic patients with haematological malignancy. *J Clin Pathol* ;42:1255-8.
- Bailey LC, Reilly AF and Rheingold SR. (2009):** Infections in pediatric patients with hematologic malignancies. *Seminars in Hematology* ;46(Issue 3):313-324.
- Balduzzi A, Valsecchi MG, Uderzo C, et al. (2005):** Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukemia in first complete remission: Comparison by genetic randomization in an international prospective study. *Lancet* ;366 (9486): 635-42.
- Baorto EP, Aquino VM, Mullen CA, et al. (2001):** Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. *Cancer* ;92:909-13.
- Bash RO, Katz JA, Cash JV, Buchanan GR, et al. (1994):** Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. *Cancer* ;74:189-96.
- Behm FG. (2003):** Classification of acute leukemias. In: Pui CH (editor). *Treatment of acute leukemias*. Hamana Press, New Jersey, Otowa : 43-58.
- Berxson EH, Dole M, Wong R, et al. (2005):** Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6- thioguanine during maintenance therapy. *Pediatr Blood Cancer* ;44 (3): 226-31.
- Bodey GP, Buckley M, Sathe YS and Frerietich EJ. (1996):** Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. *Ann Intern Med* ;64:328-340.
-

- Bostrom BC, Sensel MR, Sather HN, et al. (2003):** Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the children's cancer Group. *Blood* ;101 (10): 3809-17.
- Boutati EI and Anaissie EJ. (1997):** *Fusarium*; a significant emerging pathogen in patients with hematologic malignancy. Ten years experience at a cancer center and implications for management. *Blood* ;36:223-228.
- Brodthman D, Rosenthal D, Redner A, Lanzkowsky P and Bonagura V. (2005):** Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. *Pediatrics* ;146(5):654-661.
- Buchheidt D, Bohme A, Cornely OA, Fatkenheuer G, Fuhr HG, Heussel G, et al. (2003):** Diagnosis and treatment of documented infections in neutropenic patients: Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* ;82(Suppl 2):S127-S132.
- Burger B, Zimmermann M, Mann G, et al. (2003):** Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar Puncture. *J Clin Oncol* ;21(2):184-8.
- Castagnola E, Fontana V, Caviglia I, et al. (2007):** A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. *Clin Infect Dis* ;45(10):1296-1304.
-

- Catalano L, Fiontana R and Scarpato N. (1997):** Combined treatment with amphotericin B and granulocyte transfusion from G-CSF stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. *Haematologica* ;82:71-2.
- Caver TE, Slobod KS, Flynn PM, Behm FG, Hudson MM, Turner EV, et al. (1998):** Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia. *Leukemia* ;12:619-622.
- Charnas R, Luthi AR, Ruch W, et al. (1997):** Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. *Pediatr Infect Dis J* ;16(4):346-53.
- Clarke M, Gaynon P, Hann I, et al. (2003):** CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL collaborative group overview of 43 randomized trials. *J Clin Oncol* ;21(9):1798-809.
- Coates TD and Baehner R. (1995):** Leucocytosis and leucopenia. *Hematology basic principles and practice*; second edition by Hoffman R :769-784.
- Cohen J. (1996):** Infection in the compromised host. *Medicine Inter Group J Ltd, Middle Eastern edition* :4-11.
- Crawford J, Dale DC and Lyman GH. (2004):** Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. *Cancer* ;100:228-237.
- De Pauw B. (2004):** Preventive use of antifungal drugs in patients treated for cancer. *J Antimicrob Chemother* ;53:130-132.
- Degos L, Linch DC and Lowenberg B. (1999):** Management of infectious complications in hematological patients. *Textbook of malignant hematology* :499-517.
-

- Denning DW, Evans EG, Kibbler CC, et al. (1997):** Guidelines for the investigation of invasive fungal infections in hematological malignancies and solid organ transplantation. *Eur J Clin Microbiol Infect Dis* ;16:424-436.
- Deventer AJM, Goessens WHF, Belkum A, et al. (1995):** Improved detection of candida albicans by PCR in blood of neutropenic mice with systemic candidiasis. *Journal of clinical microbiology* :625-628.
- DiAngio GJ. (2001):** Old man river. The flow of pediatric oncology. *Hematol Oncol Clin North Am* ;15:599-607.
- Dignani CM, Anassie EJ & Hester JP. (1997):** Treatment of neutropenia- related fungal infections with granulocyte colony-stimulating factor elicited white blood cells transfusions: A pilot study, *Leukaemia* ;11:1621-30.
- Donowitz GR, Maki DG, Crnich CJ, Pappas PG and Rolston KVI, et al. (2001):** Infections in the neutropenic patient; New views of an old problem. *Hematology; American Society of hematology* :113-139.
- EK T, Mellander L, Andersson B and Abrahamasson J. (2005):** Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. *Pediatr Blood cancer* ;44: 461-468.
- El-Alfy M, Mahran M, Hossny E, et al. (1994):** Immunoglobulin G subclass deficiency in children with recurrent pneumonia. *The Egyptian journal of pediatrics* ;11(3-4):397-404.
- El-Beblawy N and Awad AS. (2001):** Fungal colonization and infection in childhood acute leukemia and lymphoma during induction therapy. *The Egyptian journal of pediatrics* ;18(3-4):411-421.
-

- El-Maghraby SM, Moneer MM, Ismail MM, Shalaby LM and El-Mahallawy HA. (2007):** The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. *J Pediatr Hematol Oncol* ;29(3):131-6.
- El-Mahallawy H, Mohamed NH, Attia EA, et al. (1999):** Risk factor evaluation and prognosis of bacteremia in children with cancer. *Journal of the Egyptian National Cancer Institute* ;11(4).
- Elting LS and Bodey GP. (1990):** Septicemia due to *Xanthomonas* species and non-aeruginosa *Pseudomonas*: Increasing incidence of catheter-related infections. *Medicine (Baltimore)* ;69:296-306.
- Engels EA, Lau & Barza M. (1998):** Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta- analysis. *J Clin Oncol* ;16: 1179-87.
- Fatkenheuer G, Buchheidt D, Cornely OA, Fuhr HG, Karthaus M, Kisro J, et al. (2003):** Central venous catheter(CVC)-related infections in neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* ;82(Suppl 2):S149-S157.
- Finke J, Ferrone S, Frey A, Mufson A and Ochoa A. (1999):** Where have all the T cell gone? Mechanisms of immune evasion by tumors. *Immunol today* ;20:158-160.
- Freifeld AG, Pizzo PA, Walsh TJ, et al. (1997):** Infections in cancer patient. *Cancer: Principles and practice of oncology*; fifth edition:2659-2704.
- Gaynon PS. (2005):** Childhood acute lymphoblastic leukaemia and replase. *Br J Haematol* ;13(5):579-87.
-

- Giamarellou H. (1995):** Empiric therapy for infections in the febrile neutropenic compromised host. *Medical Clinics of North America* volume 79, number 3.
- Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. (1996):** Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. *Eur J Clin Microbiol Infect Dis* ;15:291-296.
- Goodrich JM, Reed EC, Mori M, et al. (1991):** Clinical features and analysis of risk factors for invasive candida infection after marrow transplantation. *Clin Infect Dis* ;164:731-740.
- Greenberg D, Moser A, Yagupsky P, Peled N, Hofman Y, Kapelushnik J and Leibovitz E. (2005):** Microbiological spectrum and susceptibility patterns of pathogens causing bacteremia in pediatric febrile neutropenic oncology patients: Comparison between two consecutive time periods with use of different antibiotic treatment protocols. *Int J Antimicrob Agents* ;25:469-473.
- Hakim H, Flynn PM, Knapp KM, Srivastava DK and Gaur A. (2009):** Etiology and clinical course of febrile neutropenia in children with cancer. *J Pediatr Hematol Oncol* ;31(9):623-629.
- Hann I, Vora A, Richards S, et al. (2000):** Benefit of intensified treatment for all children with acute lymphoblastic leukemia: Results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukemia. *Leukemia* ;14(3):356-63.
- Hata M, Ogino I, Aida N, et al. (2001):** Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: Outcomes of late effects on pituitary function and growth in long-term survivors. *Int J Cancer* ;96(Suppl):117-24.
-

- Heerema NA, Nachman JB, Sather NH, et al. (1999):** Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. *Blood* ;94(12):4036-45.
- Hind CRK and Peys MB. (1984):** The role of serum C-reactive protein measurement in clinical practice. *Int Med* ;151:5-11.
- Hoffman R, Benz EJ, Shattil SJ, et al. (2000):** Clinical approaches to infections in the compromised host. *Hematology; Basic principles and practice* :1443-1500.
- Hubel K, Dale DC, Engert A & Liles WC. (2001):** Current status of granulocytes (neutrophil) transfusion therapy for infectious diseases. *J Infect Dis* ;183:321-8.
- Hughes WT, Armstrong D, Bodey GP, et al. (2002):** Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clinical infectious diseases* ;34:730-51.
- Hutchinson RJ, Gaynon PS, Sather H, et al. (2003):** Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: Long-term follow-up of patients treated on Children's Cancer Group Trial 1881. *J Clin Oncol* ;21(9):1790-7.
- Infectious Diseases Society of America guidelines, 2008.**
- Ito C, Kumagai M and Manabe A, et al. (2004):** Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: A distinct biological entity with a marked propensity to undergo apoptosis. *Blood* ;93:315.
- Jones GR, Konsler GK, Dunaway RP, et al. (1996):** Infection risk factors in febrile neutropenic children and adolescents. *Pediatr Hematol Oncol* ;13(3):217-29.
-

- Jonsson O, Sartain P, Ducore J, et al. (2003):** Bone pain as an initial symptom of childhood acute lymphoblastic leukemia. *J Pediatr* ;117:233.
- Kanafani ZA, Dakdouki GK, El-Chammas KI, Eid S, Araj GF and Kanj SS. (2007):** Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: A view of the past decade. *Int J Infect Dis* ;11(5):450-453.
- Karthaus M and Ganser A. (2000):** Supportive care in cancer patients. Recent Developments. *Antibiot Chemother. Basel Karger* ;50:69-78.
- Karthaus M, Egerer G, Kullmann KH, Ritter J, et al. (1998):** Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. *Eur J Clin Microbiol Infect Dis* ;17:501-504.
- Kavanagh DY and Carbone DP. (1996):** Immunologic dysfunction in cancer. *Hematol Oncol CLin North Am* ;10:927-951.
- Khalifa AS, Ismail MA, Hassanein SMA and Salama II. (1999):** Dietary pattern and growth of children with acute lymphoblastic leukemia. *The Egyptian journal of pediatrics* ;16(1-2):1-15.
- Khalifa AS, Mokhtar GM, El-Alfy MS, Mateir G, Youssef A, Gadallah M and Rady M. (1994):** CNS directed prophylactic therapy in ALL in children. *Egyptian Journal of Pediatrics* ;11(3-4):297-306.
- Kinnunen U, Syrjala H and Koskela M. (1996):** Continuous monitoring blood culture screening system improves the detection of bacteremia in neutropenic patients. *Scand J Infect Dis* ;28:287-292.
-

- Klaassen RJ, Goodman TR, Pham B and Doyle JJ. (2000):** "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. *J Clin Oncol* ;18(5):1012-9.
- Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. (2007):** Bacteremia in febrile neutropenic cancer patients. *Int J Antimicrob Agents* ;30(Suppl 1):S51-59.
- Klastersky J, Paesmans M, Rubenstein EB, Bayer M, et al. (2000):** The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *Journal of clinical oncology* ;18(16): 3038-3051.
- Lass-florel C, Aigner J, Gunsilius E, et al. (2001):** Screening for aspergillus spp. using PCR of whole blood samples from patients with hematological malignancies. *British journal of hematology* ;113:180-184.
- Lauer SJ, Shuster JJ, Mahoney DH, et al. (2001):** A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high risk B-precursor acute lymphoblastic leukemia; A pediatric Oncology group phase III randomized trial. *Leukemia* ;15(7):1038-45.
- Laver JH, Barredo JC, Amyion M, et al. (2000):** Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: A pediatric oncology group report. *Leukemia* ;14(3): 369-73.
- Leather HL and Wingard JR. (2002):** Prophylaxis, empirical therapy, or preemptive therapy of fungal infections in immunocompromized patient, which is better for whom? *Curr Opin Infect Dis* ;15:369-375.
-

- LeClere JM, Billett AL, Gelber RD, et al. (2002):** Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium protocol 87-01. *J Clin Oncol* ;20(1):237-46.
- Lihteh WU. (2005):** Leukemias. <http://www.emdicine.com/med/topic/489.htm>. 2005.
- Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G, et al. (1996):** The identification of febrile neutropenic children with neoplastic disease at low-risk for bacteremia and complications of sepsis. *Cancer* ;77:791-8.
- Luczynski W, Stasiak-Barmuta A and Krawezuk-Ryabk M (2004):** Immunologic monitoring of maintenance therapy for acute lymphoblastic leukemia in children. Preliminary report. *Pediatr Blood Cancer* ;42:416-420.
- Madsen K, Rosenman M, Hui S, Breitfeld PP, et al. (2002):** Value of electronic data for model validation and refinement: Bacteremia risk in children with fever and neutropenia. *J Pediatr Hematol Oncol* ;24(4):256-62.
- Mahoney DH, Shuster JJ, Nitschke R, et al. (2000):** Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy. A pediatric oncology group study. *J clin Oncol* ;16(5):1712-22.
- Margolin JF, Steuber CP and Poplack DG. (2006):** Acute lymphoblastic leukemia in: *Principles and Practice of Pediatric Oncology*. 15th ed. :538-90.
- Mensah P, Hawrylecka D and Kedzierska J. (2002):** Microbiological evaluation of oncological patients following HDC and Auto-SCT. *The Hematology Journal* ; 3 (suppl 1):404.
-

- Mitchell CD, Richards SM, Kinsey SE, et al. (2005):** Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukemia: Results of the UK medical research council ALL 97 randomized trial. *Br J Haematol* ;19(9):734-45.
- Mogharbi A, Levy DE, Asselin B, et al. (2007):** Results of the Dana-Farber cancer institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. *Blood* ;109(3):896-904.
- Moon JM and Chun BJ. (2009):** Predicting the complicated neutropenic fever in the emergency department. *Emerg Med J* ;26(11):802-6.
- Muder RR, Harris AP, Muller S, Edmond M, et al. (1996):** Bacteremia due to *Stenotrophomonas maltophilia*: A prospective multicenter study of 91 episodes. *Clin Infect Dis* ;22:508-512.
- Mullen CA, Petropoulos D, Roberts WM, et al. (1999):** Outpatient treatment of fever and neutropenia for low-risk pediatric cancer patients. *Cancer* ;86:126-34.
- Nachman J, Ather HN, Gaynon PS, et al. (2001):** Augmented Berlin-Frankfurt-Münster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the children's cancer group. *J Clin Oncol* ;15(6):2222-30.
- Nachman J, Iebel N and Sather H. (2004):** Outcome for adolescent and young adults 16-1 years of age (AYA) with ALL treated on the children's cancer group (CCG) 1961 study. *Blood* ;104:11.
- NCCN practice guidelines for fever and neutropenia, 2007.**
- Nucci M, Silverira MI, Spector N, et al. (1998):** Risk factors for death among cancer patients with fungemia. *Clinical infectious disease* ;27:107-11.
-

- Nucci M, Spector N, Bueno AP, Solza C, et al. (1997):** Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. *Clinical infectious diseases* ;24:575-9.
- Oude Nijhuis CS, Gietema JA, Vellenga E, et al. (2003):** Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. *Eur J Cancer* ;39(17):2495-8.
- Ozer H, Armitage JO & Bennett CL. (2000):** Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines. *J. Clin Oncol* ;18:3558-85.
- Paganini HR, Sarkis CM, De-Martino MG, et al. (2000):** Oral administration of cefixime to lower risk febrile neutropenic children with cancer. *Cancer* ;88(12):2848-52.
- Pagano L, Antinori A, Ammassari A, et al. (1999):** Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. *Eur J Hematol* ;63(2):77-85.
- Park Y, Kim DS, et al. (2010):** The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. *Leukemia Research* ;34:294-300.
- Paul M, Gafter-Gvili A, Leibovici L, et al. (2007):** The epidemiology of bacteremia with febrile neutropenia: Experience from a single center, 1988-2004. *Isr Med Assoc J* ;9(6):424-429.
- Pawelec G, Effors RB, Caruso C, Remarque E, Barnett Y and Solana R. (1999):** T cells and aging. *Front Biosci* ;4: D216-D269.
- Pizzo PA. (1989):** Consideration for the prevention of infectious complications in patients with cancer, *Rev Infect Dis* ;11:1551.
-

- Printer E and Krivan G. (1996):** Diagnostic value of C-reactive protein levels in children with bone marrow transplantation. *Orv Hetil* 9;137(23):1259-62.
- Pui CH and Crist WM. (2001):** Biology and treatment of acute lymphoblastic leukemia. *J pediat* ;124: 491.
- Pui CH and Evans WE. (2006):** Acute lymphoblastic Leukemia. *N Engl J med* ;354(2):166-78.
- Pui CH, Relling MV and Downing JR. (2004):** Acute lymphoblastic Leukemia. *N Engl J med* ;350(15):1535-48.
- Pullen J, Boyett J, Shuster J, et al. (2002):** Extended triple intrathecal chemotherapy trail for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic Leukemia: A Pediatric Oncology Group study. *J clin oncol* ;11(5): 839-49.
- Raad I, Narro J, Khan A, Tarrand J, et al. (1992):** Serious complications of vascular catheter-related staphylococcus aureus bacteremia in cancer patients. *Eur J Clin Microbiol Infect Dis* ;11:675-682.
- Rackoff WR, Gonin R, Robinson C, et al. (1996):** Predicting the risk of bacteremia in children with fever and neutropenia. *J Clin Oncol* ;14:919-924.
- Ramphal R. (2004):** Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. *Clin Infect Dis* ;39:S25-31.
- Rex JH, Bennett JE, Sugar, et al. (1995):** Intravascular catheter exchange and the duration of candidemia. *Clinical infectious disease* ;21:994-6.
-

- Riikonen P, Jalanko H, Hovi L, Saarinen UM, et al. (1993):** Fever and neutropenia in children with cancer: Diagnostic parameters at presentation. *Acta Paediatr* ;84:271-5.
- Rintala E, Irjala K, Nikoskelainen J, et al. (1992):** Value of measurement of C-reactive protein in febrile patients with hematological malignancies. *Eur J Clin Microbiol Infect Dis* ;p.973-978.
- Rivera GK, Pinkel D, Simone JV, et al. (2003):** Treatment of acute lymphoblastic leukemia. 30 years experience at St. Jude children's research hospital. *N Engl J Med* ;329(18):1289.
- Rondinelli PI, Ribeiro KD and de Camargo B. (2006):** A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. *J Pediatr Hematol Oncol* ;28 (10):665-70.
- Rubenstein EB, Rolston K, Beniamin RS, et al. (1993):** Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. *Cancer* ;71:3640-6.
- Rubnitz JE. (2005):** Acute lymphoblastic leukemia 2005. <http://www.emdeicine.com/med/topic 2587.htm>.
- Saeidpour M, Hamedi AK and Hanachi P. (2008):** Pattern of bacterial and fungal infections in neutropenic pediatric patients. *Iranian J Med Sci* ;33(4).
- Santolaya ME, Alvarez AM, Aviles CL, Becker A, Cofre J, Enriquez N, et al. (2002):** Prospective evaluation of a model of prediction of invasive bacterial infection among children with cancer, fever, and neutropenia. *Clin Infect Dis* ;35(6):678-83.
-

- Santolaya ME, Alvarez AM, Aviles CL, Becker A, Mosso C, O'Ryan M, et al. (2007):** Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. *Pediatr Infect Dis J* ;26(9):794-8.
- Santolaya ME, Alvarez AM, Becker A and Cofre J. (2001):** Prospective, Multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. *Journal of clinical microbiology* ;19(14):3415-3421.
- Saral R. (1991):** Candida and aspergillus infections in immunocompromised patients: An overview. *Rev Infect Dis* ;13:487-492.
- Scharppe M, Reiter A, Ludwig WD, et al. (2000):** Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German Austrian-Swiss ALL-BFM Study Group. *Blood* ;95(11): 3310-22.
- Schimpff SC. (1993):** Gram-negative bacteremia. *Support Care Cancer* ;1:5-18.
- Schultz KR, Pullen DJ, Sather NH, et al. (2007):** Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). *Blood* ;109(3):926-35.
- Seiter K. (2004):** Acute lymphoblastic leukemia 2004. [http://www.emedicine.com/med/topic3146 . htm](http://www.emedicine.com/med/topic3146.htm).
- Shenep JL, Flynn PM, Baker DK, et al. (2001):** Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. *Clinical infectious diseases* ;32:36-43.
-

- Shumacher HR. (2002):** Acute leukemia. Clin Lab Med ;22:153-192.
- Shuster JJ, Camitta BM, Pullen J, et al. (1999):** Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse. Cancer Research, Therapy and Control ;9(1-2):101-107.
- Silverman LB and Sallan SE. (2003):** Newly diagnosed childhood acute lymphoblastic leukemia. Curr Opin Hematol ;10:290-296.
- Silverman LB, Gelber RD, Dalton VK, et al. (2001):** Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01 Blood ;97(5):1211-8.
- Smith M, Arthur D, Camitta B, et al. (1996):** Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol ;14(1):18-24.
- Spirito FR, Mancini M, Dermi V, Cimino G. Testi AM, Tafuri A, Vitale A and Foa R. (2003):** Trisomy 13 in a patient with common acute lymphoblastic leukemia: Description of a case and review of the literature. Cancer Genet Cytogenet ;144(1): 69-72.
- Spreadbury C, Holden D, Bainbridge B, et al. (1993):** Detection of aspergillus fumigatus by polymerase chain reaction. Journal of clinical microbiology :p.615-621.
- Stabell N, Nordal E, Stensvold E, et al. (2007):** Febrile neutropenia in children with cancer: A retrospective Norwegian multicenter study of clinical and microbiological outcome. Scand J Infect Dis ;4:1-7.
- Stahnke K, Fulda S, Friesen C, StrauB G and Debatin KM. (2001):** Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood ;98:3066-3073.
- Tacyildiz N. (2002):** Six years experience of fungemia in a pediatric oncology center in Turkey. The Hematology Journal ;3(suppl 1): 423.
-

- te Poele EM, Tissing WJ, Kamps WA and de Bont ES. (2009):** Risk assessment in fever and neutropenia in children with cancer: What did we learn? *Crit Rev Oncol Hematol* ;72(1):45-55.
- The Brooklyn Antibiotic Resistance Task Force. (2002):** The cost of antibiotic resistance: Effect of resistance among staphylococcus aureus, klebsiella pneumonia, acinetobacter baumannii and pseudomonas aeruginosa on the length of hospital stay. *Infect Control Hosp Epidemiol* ;23:106-108.
- Uzun O and Anaissie EJ. (2000):** Predictors of outcome in cancer patients with candidemia. *Annals of oncology* ;11:1517-1521.
- Van de Wetering, Poole J, Friedland I, et al. (2001):** Bacteremia in pediatric oncology unit in South Africa. *Med Pediatr Oncol* ;37:525-531.
- Vartivarian SE, Anaissie EJ, Bodey GP, et al. (1993):** Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis and management. *Clin Infect Dis* ;17(suppl 2):487-491.
- Velasco E, Byington R, Martins CS, Schirmer M, Dias LC and Goncalves VM. (2004):** Bloodstream infection surveillance in a cancer center: a prospective look at clinical microbiology aspects. *Clin Microbiol Infect* ;10(6):542-549.
- Verduyn-Lunnell FM, Meis JF, Voss A, et al. (1999):** Nosocomial fungal infections. *Diagn Microbiol Infect Dis* ;34(3):213-20.
- Villarroel M, Aviles CL, Silva P, Guzman AM, Poggi H, Alvarez AM, et al. (2010):** Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: A prospective multicenter evaluation. *Pediatr Infect Dis J* ;29 (9):816-21.
- Viscoli C, Castagnola E and Machetti M. (1997):** Antifungal treatment in patients with cancer. *J Intern Med* ;242(suppl 740):89-94.
-

- Viscoli C, Varnier O and Machetti M. (2005):** Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. *Clin Infect Dis* ;40(Suppl 4):S240-245.
- Waber DP, Shapiro BL, Carpentieri SC, et al. (2001):** Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: A 7-year follow up study of the Dana-Farber Cancer institute consortium protocol 87-01. *Cancer* ;92(1):15-22.
- Wade JC and Rubenstein EB. (2001):** NCCN fever and neutropenia practice Guidelines panel: NCNN: Fever and neutropenia. *Can Control* 8/6 (suppl 2): 16-2.
- Wehl G, Allerberger F, Heitger A, et al. (1999):** Trends in infection morbidity in a pediatric oncology ward, 1986-1995. *Medical and pediatric oncology* ;32:336-343.
- Wingard JR. (2004):** Empirical antifungal therapy in treating febrile neutropenic patients. *Clin infect Dis* ;39(Suppl 1):S35-S43.
- Wisplinghoff H, Seifert H, Wenzel RP and Edmond MB. (2003):** Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematologic malignancies and solid neoplasms in hospitals in the United States. *Clin Infect Dis* ;36:1103-10.
- Wooderuff TJ, Axelrad DA, Kyle AD, Nweke O, Miller GG and Huyrley BJ. (2004):** Trends in environmentally related childhood illnesses. *Pediatrics* ;113:1133-1140.
- Yoo JH, Choi SM, Lee DG, Choi JH, Shin WS, Min WS, et al. (2005):** Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea. *J Korean Med Sci* ;20:31-5.
-

Yoshida M, Karasawa M & Naruse T. (1999): Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef of sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group Int J Hematol ;69:81-8.

Yule M. (1998): The supportive care for children receiving treatment for cancer. Voute P.A: Cancer in children: Clinical management :71-83.